Skip to main content
. 2017 Dec 1;8(70):114698–114709. doi: 10.18632/oncotarget.22815

Figure 3. Relative expression of HSPA1A/HSPA1B, HSPA5, HSPA8, XBP-1 and Beclin-1 genes in bioluminescent cell lines.

Figure 3

(A) RPMI8226-LUC-PURO untreated versus RPMI8226-LUC-PURO treated with bortezomib (100 nM) or VER155008 (50 μM or 80 μM) or bortezomib plus VER155008 (50 μM or 80 μM). (B) U266-LUC-PURO untreated versus U266-LUC-PURO treated with bortezomib or VER155008 (50 μM or 80 μM) or bortezomib plus VER155008 (50 μM or 80 μM). Relative expression was performed using 2−DDCt formula, with β-actin as housekeeping gene and untreated cell line as reference. One-Way ANOVA, with Bonferroni’s post -test.